about
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeThe EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.Health-related quality of life in multiple sclerosis: effects of natalizumab.Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyMyxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J MeDefining secondary progressive multiple sclerosis.Predictors of long-term disability accrual in relapse-onset multiple sclerosis.Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsThe effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.Oral BG-12 in multiple sclerosis.Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis.Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis.Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
P50
Q24605493-6054E95B-542D-4EA2-8CC5-5B9E8085ABB9Q28480907-AD67E32F-0DE8-4056-877E-C6C7AADE5B0DQ30277106-5CA9B900-4030-43F9-924F-12C71D9DD512Q34300614-E0907382-83F3-4EF0-BA88-65A0B9983312Q34483022-C8869152-3B65-47E7-807D-F689195140B5Q34548374-8F979152-FF79-4532-BEE5-3696CD063F13Q34656844-EA0B6F78-56E8-4FDA-AF86-20B6A94B27B1Q34662511-6D24A210-3796-464F-BFCB-FEBB06AB060FQ35032818-8BC71C42-4D47-4189-BF51-D869B71956C4Q35211079-434A8C1E-4022-4A21-9C30-52EDD93DEBD3Q36247683-22CE736C-D66D-48D3-B98B-90EC3E4A9F68Q36282742-2612ECB2-E64F-4312-9877-5F525403DC87Q36389688-2F33E8A9-0D41-4730-90D0-8349158A778EQ36801041-90A31C12-5C44-42C7-B807-14515981FC6DQ37459065-55B2A750-C405-45D3-B8D9-12651615C150Q37982013-FE6ED0D7-2360-4694-A6C7-E6F144D33A4BQ38131058-C56FBCA1-A668-4170-BB3A-D8602F55E25BQ38843046-7DFE2C2E-F663-49EA-865F-68855E6097E1Q39795220-176A8F4D-FDC6-4C05-93C3-5D28DC599C8EQ39891381-8AEF07E0-EC4B-4300-B98E-58AAC5AA4DD4Q40412270-A1562B93-6233-409A-87F6-301F988BA172Q40710140-4C1D49AD-3CCB-4394-8D5F-DA0BBD3D2664Q41459651-8941B582-EE60-4438-9599-6A0FD1A89FB6Q43765361-628693AA-B622-4C0D-A178-8A0066C9DF56Q45463159-E19FA101-B07C-411F-9944-2A3F495D3E4FQ45890653-B603F495-9511-45DB-9803-0ED2745D332CQ46148199-BAB4F222-38D0-4078-B67A-AEACDDDA9C85Q46934652-39B5DE85-90D5-4069-9F35-77D0D29A79ADQ48154852-32EA6236-1A6C-40B3-B117-FDA3863B8954Q48329925-7F582074-11B6-4307-ABAD-597DF3D28B68Q48431460-90D556C1-12A7-42EC-9007-7C36025FF31AQ48700127-CED880E2-8EAA-4DC3-81B0-4C2B477AC6B8Q49108125-FF1BA0CE-9E3D-4279-A1AE-73FA3ACD9883Q50666756-4628E8E9-0B5A-4A7A-B7BB-BE4793FD1647Q51062974-945F78A5-33EE-4515-8CD2-96E9A623A731Q51648841-E1590159-40D7-4CF4-A7E8-589A3F2A0A30Q52141693-274E3C14-EBC4-4824-834B-847FAD41BBDDQ52149416-657830B8-1336-4594-A911-8534A03AF013Q53078951-9663B02A-AC13-4681-89E4-9715B9F18726Q53326795-8BA0BE3F-65DE-42C4-B656-9E01215AC1BA
P50
description
doctor and researcher of multiple sclerosis
@en
lékařka, vědkyně a pedagožka
@cs
médecin et scientifique
@fr
onderzoeker
@nl
Ärztin und Forscherin
@de
հետազոտող
@hy
name
Eva Havrdova
@ast
Eva Havrdova
@en
Eva Havrdova
@es
Eva Havrdova
@sl
Eva Havrdová
@cs
Eva Havrdová
@de
Eva Havrdová
@fr
type
label
Eva Havrdova
@ast
Eva Havrdova
@en
Eva Havrdova
@es
Eva Havrdova
@sl
Eva Havrdová
@cs
Eva Havrdová
@de
Eva Havrdová
@fr
prefLabel
Eva Havrdova
@ast
Eva Havrdova
@en
Eva Havrdova
@es
Eva Havrdova
@sl
Eva Havrdová
@cs
Eva Havrdová
@de
Eva Havrdová
@fr
P1053
P-4892-2017
P106
P1153
26642961800
P21
P31
P3829
P496
0000-0002-9543-4359